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Abstract
The genetically heterogeneous triple-negative breast cancer (TNBC) continues to be an intractable disease, due to lack of
effective targeted therapies. Gene amplification is a major event in tumorigenesis. Genes with amplification-dependent
expression are being explored as therapeutic targets for cancer treatment. In this study, we have applied Analytical Multi-
scale Identification of Recurring Events analysis and transcript quantification in the TNBC genome across 222 TNBC tumors
and identified 138 candidate genes with positive correlation in copy number gain (CNG) and gene expression. siRNA-based
loss-of-function screen of the candidate genes has validated EGFR, MYC, ASAP1, IRF2BP2, and CCT5 genes as drivers
promoting proliferation in different TNBC cells. MYC, ASAP1, IRF2BP2, and CCT5 display frequent CNG and concurrent
expression over 2173 breast cancer tumors (cBioPortal dataset). More frequently are MYC and ASAP1 amplified in TNBC
tumors (>30%, n= 320). In particular, high expression of ASAP1, the ADP-ribosylation factor GTPase-activating protein, is
significantly related to poor metastatic relapse-free survival of TNBC patients (n= 257, bc-GenExMiner). Furthermore, we
have revealed that silencing of ASAP1 modulates numerous cytokine and apoptosis signaling components, such as IL1B,
TRAF1, AIFM2, and MAP3K11 that are clinically relevant to survival outcomes of TNBC patients. ASAP1 has been
reported to promote invasion and metastasis in various cancer cells. Our findings that ASAP1 is an amplification-dependent
TNBC driver gene promoting TNBC cell proliferation, functioning upstream apoptosis components, and correlating to
clinical outcomes of TNBC patients, support ASAP1 as a potential actionable target for TNBC treatment.
Introduction
Triple-negative breast cancer (TNBC) represents a particu-
larly proliferative and aggressive subtype of breast cancer
(BC), associated with large size of tumors, high mitotic rate
of tumor cells, high tumor grade and metastasis, causing
poor prognosis and high mortality rate of patients [1].
TNBC constitutes 15–20% of BC, being clinically char-
acterized by the lack of expression of estrogen receptor
(ER), progesterone receptor (PR), and the absence of
amplification of human epidermal growth factor receptor 2
(HER2), which are the known drivers of other BC types [2].
The absence of actionable targets defined in TNBC cells
leads to clinical failure of targeted therapies in TNBC
patients. Cytotoxic chemotherapy remains the conventional
systemic treatment for TNBC patients, resulting in adverse
effects and unfavorable outcomes [3, 4]. Identification of
actionable targets for TNBC treatment is a continuous
effort.
Gene copy number alterations (CNAs) are a hallmark in
the cancer genome [5]. Gains or losses of gene copy are
important somatic genomic aberrations contributing to
tumorigenesis [6]. Changes in gene copy number result in
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corresponding changes in expression of the affected genes,
causing phenotypes [7]. Copy number gains (CNGs),
increasing from the two DNA copies present in normal
diploid genome, sometimes to several hundred copies
(known as amplification), are observed to frequently occur
on cancer driver genes [8, 9]. Oncogenic driver genes with
increase in DNA copy number and expression have been
identified and explored as potential drug targets for targeted
therapies in cancer [10]. For instance, the HER2 gene,
which is amplified in ~30% of primary BCs [11], has been
proven as an actionable target for trastuzumab antibody
targeted therapy and lapatinib inhibitor targeted therapy
treating patients with HER2-amplified BC [12]. Therefore,
identification of CNG-driven genes and their amplification-
dependent overexpression provides opportunities for dis-
covering potential cancer driver genes as therapeutic targets
for therapy-refractory cancer.
A number of studies have demonstrated the genomic
heterogeneity in TNBCs, being dominated by substantial
mutational burdens, including CNAs and genomic rearran-
gements [6, 13]. CNA genomic profiling based on separate
TNBC sample groups have reported the TNBC-related
recurrent CNAs on various chromosome regions [14]. Yet,
integrative analysis of CNG frequency and CNG-driven
gene expression in the TNBC genome is limited.
In this study, we applied the Analytical Multi-scale
Identification of Recurring Events (ADMIRE) algorithm to
identify candidate driver genes that are frequently amplified
by recurrent CNGs, in correlation with their RNA expres-
sion levels, in 222 triple-negative tumors from TCGA (n=
118) [15] and Metabric (n= 104) [2] datasets. As a result,
138 genes were identified, with a significant and positive
correlation in their gene amplification and expression.
These amplification-driven genes were subsequently vali-
dated by loss-of-function screen for their biological function
in TNBC cell proliferation, followed by assessment of their
expression and amplification in broad BC cell lines and
tumors, and evaluation of their clinical relevance using
multiple large public BC datasets [16, 17]. Consequently,
we characterized the known oncogenes MYC and EGFR
and the novel candidate genes ASAP1, IRF2BP2, and
CCT5 as cancer drivers in promoting proliferation of TNBC
cells. MYC and ASAP1 were observed to be more fre-
quently amplified and highly expressed in TNBC than non-
TNBC tumors. Specifically, high expression of ASAP1, an
ADP-ribosylation factor (Arf) GTPase-activation protein
regulating cell motility and invasiveness [18], is sig-
nificantly relevant to poor metastatic relapse-free survival
(MRFS) of patients with TNBC tumors, not non-TNBC
tumors. Transcriptome analysis further revealed that
ASAP1 regulates various cytokine and apoptosis signaling
components that are significantly associated with TNBC
prognosis. Our work discovered ASAP1 as an
amplification-dependent gene driving TNBC proliferation,
survival and progression, supporting the potentiality of
ASAP1 as a therapeutic target for the treatment of TNBC.
Results
ADMIRE analysis of TNBC genomes identifies TNBC
candidate driver genes with recurrent copy number
gain and correlated expression
Recurrent CNAs have been recognized as the result of
natural selection in tumor evolution, and hence the recur-
rently altered regions are likely to harbor cancer driver
genes [19]. In order to identify candidate driver genes for
TNBC, we applied ADMIRE, a robust algorithm for the
discovery of broad and focal recurring events [20], to detect
genomic regions with frequent CNAs in a set of TNBC
tumors (n= 118 for TCGA; n= 104 for Metabric).
Aggregated DNA copy number profiles (Fig. 1a) assisted in
pinpointing recurrently altered regions (Fig. 1b). Genes
contained in the focal regions were further assessed with
copy number and expression correlation analysis (Fig. 1c).
Genes showing positive correlation in mRNA expression
levels and copy numbers were filtered out as candidate
drivers, as exemplified for the proto-oncogene MYC (Fig.
1d). The ADMIRE analysis and the subsequent filtering
steps were performed separately for TCGA and Metabric
cohorts. Subsequently, 138 genes were selected as candi-
date driver genes for TNBC (Supplementary Table 1). Next,
functional enrichment analysis displayed the significant
implication of the 138 genes in 18 KEGG pathways (Sup-
plementary Fig. 1). The 138 gene set was enriched in
cancer-related pathways, including central carbon metabo-
lism in cancer, proteoglycans in cancer, pathways in cancer,
melanoma, prostate cancer, and endometrial cancer. More-
over, these candidate drivers were implicated in various
oncogenic signaling pathways that control cell growth,
survival, and motility, such as ErbB, PI3K-Akt, Ras,
MAPK, and Wnt pathways. Altogether, our ADMIRE
genomics approach collected 138 candidate TNBC drivers
that are frequently amplified by recurrent CNGs in the
TNBC genome and significantly enriched in pathways that
fuel cancer progression.
Loss-of-function screen validates the TNBC
candidate driver genes in TNBC cell proliferation
As a first step, we assessed the biological function of the
138 candidate genes in control of TNBC cell proliferation
by siRNA-mediated loss-of-function screen in two TNBC
cell lines, mesenchymal-like BT549 and basal-like
SUM149T. High reproducibility was achieved for the
J. He et al.
Fig. 1 Schematic selection of candidate driver genes with increases
in copy number and expression in TNBC genome. a Discovery of
genomic regions with recurrent copy number alterations using
ADMIRE analysis. The top panel shows the aggregate copy number
profile across 222 triple-negative breast tumors (n= 118 for TCGA;
n= 104 for Metabric). The bottom panel shows the significant
recurrent copy number regions, with gains in green and losses in red.
b Zoomed in fragment of panel a, focusing on chromosome 8. The
bottom panel reveals the small focal recurrent copy number gain on 8q
for further analysis. c The genes contained in the focal region identi-
fied in panel b. d Scatterplot exemplifying the positive correlation of
MYC gene expression with its copy number in TNBC patients.
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duplicate screens in BT549 (r= 0.9212) and SUM149PT
(r= 0.9127) (Fig. 2a). Genes whose silencing controlled
proliferation <60% were considered as candidate hits with
significance (Fig. 2b). Consequently, 41 primary hits were
screened for BT549 and 20 for SUM149PT cell line (Fig.
2b, c). In total, 46 primary hits were selected, of which 15
were common (Fig. 2d; Supplementary Table 2).
Next, we examined the CNG frequency of the 46 primary
hits in 20 TNBC cell lines, representative for diverse
molecular subtypes of TNBC. Ten candidate hits were
found with CNG frequency across ≥8 TNBC cell lines (Fig.
3a, lower panel). The CNG recurrence for MYC was found
in 16/20 of TNBC cell lines, ASAP1 in 15/20, ANKH,
CCT5, and EGFR in 12/20, IRF2BP2 in 10/20, BNIP1,
DRD1, SFXN1, and TMEM67 in 8/20, respectively. We
also evaluated the mRNA expression level of the 46 pri-
mary hits in the 20 TNBC cell line panel in our established
RNA-Seq data (Fig. 3a, upper panel). Given the nature of
heterogeneity of TNBC, the correlation of expression and
copy number of the primary hits varied among cell lines.
To further validate the ten candidate hits for their function
in proliferation, we performed siRNA silencing in three
TNBC cell lines, BT549, SUM149T, and one more
mesenchymal-like cell line Hs578T. Silencing of six hits,
ASAP1, CCT5, IRF2BP2, DRD1, and two known oncogenes
MYC and EGFR, potently inhibited proliferation (>50%) in
all three cell lines (Fig. 3b), suggesting their driving role in
TNBC cell proliferation. Deconvolution siRNA screen con-
firmed the effect of single siRNAs (≥2/4) on the proliferation-
driving hits, mostly achieving >50% of proliferation inhibi-
tion, ruling out the off-targeting effect of pooled siRNAs (Fig.
3c). The optimized pooled siRNA silencing further validated
the function of the driver hits in proliferation control (>50%)
(Fig. 3d). Of note, the inhibitory effects on cell proliferation
by silencing these six hits were, in general, concordant with
CNA status in these cell lines (Fig. 3e).
Collectively, our RNAi-based functional screen validated
the ADMIRE-identified candidate driver genes and defined
the role of MYC, EGFR, ASAP1, IRF2BP2, CCT5, and
DRD1 in controlling proliferation of TNBC cells.
Frequent amplification of ASAP1 in TNBC is
significantly relevant to poor clinical outcome
We next sought to address the correlation between CNA
frequencies and expression levels of MYC, EGFR,
Fig. 2 siRNA-mediated loss-of-function screen of candidate driver
genes in TNBC cells. a Replicate siRNA screens of candidate driver
genes in TNBC cell lines BT549 and SUM149T. siRNA silencing
effect of candidate gene on cell proliferation was assessed 96 h after
transfection and presented with sulforhodamine B (SRB) colorimetric
raw values. b Normalized percentage of proliferation control by
siRNA silencing. The number of genes (black) whose silencing led to
>40% proliferative inhibition was indicated in the pie chart, as primary
hits. c Ranking and listing of the primary hits significantly controlling
proliferation of BT549 and SUM149PT TNBC cell lines. siRNA tar-
geting KIF11, positive functional control; siCtrl, non-targeting siRNA
control. siRNA silencing effect on proliferation was relative to siCtrl.
Error bars indicate variation of screen replicates. d Overlap primary
hits in BT549 and SUM149T TNBC cell lines.
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ASAP1, IRF2BP2, CCT5, and DRD1 in broad BC cell
lines and breast tumors and the clinical relevance of the
genes to patients with BC. RNA-Seq analyses of the
transcriptome from our 52 BC cell lines demonstrated
Fig. 3 Validation of candidate driver genes with concurrent copy
number gain (CNG) and overexpression in TNBC cells. a mRNA
expression of 46 primary hits in 20 TNBC cell lines. Violin plot
indicates Log2 mRNA expression level of 46 primary hits in 20 TNBC
cell lines retrieved from RNA-Seq analysis. Bars indicate CNG fre-
quency of the hits in 20 TNBC cell lines. Genes with frequent CNG in
≥8/20 TNBC cell lines were marked in red. b siRNA validation of
primary candidate hits with high frequent CNG in BT549, Hs578T,
and SUM149PT TNBC cell lines. SMARTpool siRNAs were used to
target each hit. KIF11 was taken as positive control. c siRNA
deconvolution validation of six candidate driver hits. The effects of
SMARTpool (p) siRNA and single siRNA_1, _2, _3, and _4 on hits
were compared for their proliferation control (%) in the TNBC cell
lines. d Percentage of control proliferation (%) by optimized
SMARTpool siRNAs targeting the six candidate hits. The results were
expressed as mean ± SEM of three independent experiments. e CNA of
the six candidate driver genes in TNBC cell panel. “++”, high CNG;
“+”, CNG; “/”, no copy number alteration; “−”, copy number loss.
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that the Log2-based mRNA expression levels of MYC,
EGFR, ASAP1, and CCT5 were higher in TNBC than
non-TNBC cell lines (Supplementary Table 3), while
similar high IRF2BP2 and low DRD1 were expressed in
both cell types (Fig. 4a). The difference of EGFR
expression in TNBC and non-TNBC cells was of sig-
nificance. Next, we obtained Z score-based mRNA
expression data for the hits in 1904 BC tumors from
cBioPortal database [2, 17, 21]. MYC, EGFR, ASAP1
and IRF2BP2 were highly expressed in TNBC, compared
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with non-TNBC tumors (Fig. 4b). CCT5 expression was
found lower in TNBC than non-TNBC breast tumors, and
DRD1 showed no significant difference. We further
illuminated the correlation between CNAs and expression
levels of the genes in the cohort of 1904 BC tumors.
While CNA events in deep or shallow depletion rarely or
less occurred, EGFR, MYC, IRF2BP2, ASAP1, and
CCT5 (except for DRD1) often underwent copy gain and
amplification, acquiring CNA-driven expression in the
breast tumors (Fig. 4c). Moreover, MYC, ASAP1, and
IRF2BP2 were amplified in >20% of all 2173 BC tumors
(Fig. 4d). Particularly, MYC and ASAP1 amplifications
emerged more frequently in TNBC tumors (>30%),
suggesting TNBC subtype-related MYC and ASAP1
amplifications. Prognostic analysis demonstrated the
association of the CNA-driven hits with overall survival
(OS) of the cohort of 1981 BC patients [2, 21], indicating
the significant implication of MYC and ASAP1 in poor
disease outcomes (Supplementary Fig. 2). More specifi-
cally, high ASAP1 expression was revealed to be related
to worse MRFS of patients with TNBC (n= 257), but not
ER+ BC (n= 2519) (Fig. 4e), as assessed in the cohorts
of BC patients [16]. Together, we characterized MYC and
ASAP1 as CNA-driven genes with frequent amplification
and concurrent high expression in BC tumors. The CNA-
driven amplification and expression of ASAP1 exhibited
significant clinical impact particularly on TNBC
progression.
Transcriptomic analysis of the impact of ASAP1
depletion on gene expression in TNBC cells
Amplification or deletion of a gene copy may affect the
expression of genes located outside the amplified/deleted
region itself via indirect mechanisms [22, 23]. The ASAP1
gene, located at chromosome 8q24.21, encodes an Arf
GTPase-activating protein that induces hydrolysis of GTP
bound to Arf proteins. ASAP1 has been reported to be
involved in signal transduction, membrane trafficking, and
cytoskeleton remodeling [24] and promote proliferative,
invasive, and metastatic phenotypes of various cancer cells
[18, 25]. Whether CNA-driven ASAP1 amplification and
overexpression influence gene expression at a genome-wide
level in cancer cells is not addressed. To this end, we per-
formed TempO-Seq-based targeted whole genome RNA
sequencing in the three TNBC cell lines BT549, Hs578T,
and SUM149PT that harbor ASAP1 amplification and high
expression (Fig. 3e). The cells were transfected with siRNA
targeting ASAP1 (siASAP1) or non-targeting siCtrl in
biological triplicate, respectively. The transcriptome
TempO-Seq assays were run at a read depth of 6.8 M per
sample (Supplementary Fig. 3a), achieving reproducibility
with Pearsonʼs r values over 0.95 (Supplementary Fig. 3b).
Principal components analysis of global changes in gene
expression clustered various gene expression patterns across
cell lines and transfections (Supplementary Fig. 3c). Using
DESeq2 package in R, the Log2 normalized transcriptome
profiles displayed the differential effects of ASAP1 deple-
tion on gene expression in the TNBC cells (Fig. 5a).
siRNA-mediated knockdown reduced >45% of mRNA
expression of ASAP1 in the TNBC cells (Fig. 5b, left
panel), warranting the effective knockdown of ASAP1 itself
(Log2 FC −0.7 to −1.5) in the TempO-Seq transcriptome
panels (Fig. 5b, right panel). Genes with twofold changes
(absolute Log2 FC ≥1) in down- or up-regulation (p value
< 0.05) were selected in BT549 (311 down/495 up), Hs578T
(133 down/117 up), and SUM149PT (500 down/401 up) cells,
respectively (Fig. 5c). Venn diagrams extracted differentially
expressed genes (DEGs) that were significantly down- or
upregulated by ASAP1 depletion in the TNBC cell lines (Fig.
5d; Supplementary Table 4). Consequently, 95 DEGs were
downregulated, and 79 DEGs upregulated in ≥2/3 of the
TNBC cell lines, in total 174 DEGs, which were considered as
common DEGs that were susceptible to the depletion of the
amplification-dependent ASAP1.
ASAP1 regulates cytokine and apoptosis signaling
components that are associated with TNBC
prognosis
Next, to evaluate the biological functions of 174 common
DEGs that were susceptible to ASAP1 depletion, we con-
ducted Metascape Pathway and process enrichment analysis
integrating the gene ontology sources, including GO Bio-
logical Process, KEGG pathway, Reactome Gene Sets,
Canonical Pathways, and CORUM [26]. Top 20 clusters
were defined with their representative enriched terms (Fig.
6a, left; Supplementary Table 5), including cytokine sig-
naling pathways (cytokine signaling in immune system,
response to interleukin-1, TNF-signaling pathway, and
regulation of inflammatory response), metabolic processes
(regulation of lipid metabolic process and regulation of
Fig. 4 ASAP1 amplification and overexpression in TNBC in
association with poor clinical outcome. a Log2-based mRNA
expression of the six candidate hits in 52 breast cancer (BC) cell lines.
Log2 values were obtained from established RNA-Seq data (two-way
ANOVA ***p < 0.001). b Z score-based mRNA expression of the hits
in 1904 BC tumors. Data were retrieved from the dataset “METAB-
RIC, Nature 2012 & Nat Commun 2016” in cBioPortal dataset.
c Correlation between CNA and gene expression of the candidate hits
in the cohort of 1904 BC tumors. Different copy number amplifica-
tions (deep deletion, shallow deletion, diploid, gain, and amplification)
are presented per gene. d Amplification frequency of the candidate hits
in the cohort of 2173 BC tumors. Data were retrieved from the dataset
“METABRIC, Nature 2012 & Nat Commun 2016” in cBioPortal
dataset. eMRFS Kaplan–Meier (KM) curve of ASAP1 in TNBC (n=
257) and ER+ BC (n= 2519) cohorts analyzed by bc-
GenExMiner v4.2.
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sulfur metabolic process), apoptosis signaling pathways
(regulation of apoptosis signaling pathway and positive
regulation of cell death), MAPK pathways (regulation of
p38 MAPK cascade and MAPK signaling pathway), cell
cycle arrest, and P53 downstream pathway. Furthermore,
network enrichment captured the interactions between the
20 clusters, as visualized using Cytoscape (Fig. 6a, right).
Strikingly, among the 20 clusters, the cytokine signaling in
immune system, regulation of lipid metabolic process, and
regulation of apoptotic signaling pathway were most sig-
nificantly enriched. Protein–protein interaction clustering
algorithm identified neighborhoods within the networks
where the ASAP1-regulated genes were densely connected,
such as ANXA1, C3, CXCL1, CXCL2, and CXCL8 node
(involved in immune response), IMPDH1, PSMC4, and
RAN node (involved in nucleotide and protein metabolism),
and APEX1, MCM6, and RBL2 node (involved in cell
cycle G1/S phase transition) (Fig. 6b). These results
revealed the novel and essential biological functions of
ASAP1 in multiple molecular pathways.
Around 45% of ASAP1-regulated genes (78/174) were
involved in cytokine signaling pathways (Supplementary
Table 6), being interactive in cytokine signaling in immune
system, response to interleukin-1, TNF-signaling pathway,
and regulation of inflammatory response. In regulation of
apoptosis signaling and cell death pathways, 33 genes were
modulated by ASAP1 depletion. Unsupervised hierarchical
heatmap classified the 21 positive and 20 negative reg-
ulators in cytokine signaling pathways, 5 positive and 10
negative regulators in lipid metabolism pathway, and 8
positive and 9 negative regulators in apoptosis signaling
pathways (Fig. 6c), in the BT549, Hs578T, and SUM149PT
TNBC cell lines. As cytokine signaling pathways, e.g.,
TNF-signaling pathway, mediate extrinsic/intrinsic apopto-
sis [27], crosstalk might exist in the ASAP1-regulated
cytokine and apoptosis signaling pathways. Indeed, among
33 ASAP1-regulated apoptosis genes, 23 genes (~70%)
were interactive in cytokine signaling pathways (Supple-
mentary Table 6), further stressing the implication of
ASAP1 as a driver gene in cell survival and growth.
Crosstalk was also observed between ASAP1-regulated
genes in lipid metabolic process (17/31, ~50%) and cyto-
kine signaling (Supplementary Table 6). To explore the
association between these ASAP1-regulated cytokine, lipid
metabolism and apoptosis genes and the survival of patients
with TNBC, we performed Kaplan–Meier (KM) survival
analysis using KM plotter [28]. The results exhibited that,
based on the mean expression of the selected genes in
TNBC tumors, a low expression level of the negative reg-
ulators, which were downregulated under ASAP1 depletion,
Fig. 5 Targeted whole transcriptome analysis of ASAP1 depletion-
induced transcription reprogramming in TNBC cells. a Tran-
scriptome expression profiling in BT549, Hs578T and SUM149PT
TNBC cells after siRNA-mediated depletion of ASAP1 (siASAP1).
Log2 fold change (Log2 FC), siASAP1 versus siCtrl. b Targeting
effect of siASAP1 on ASAP1 gene expression. Left panel, knockdown
efficiency assessment by RT-qPCR (two-way ANOVA *p < 0.05, **p
< 0.01). TNBC cells were transfected with optimized SMARTpool
siRNAs for 72 h. GAPDH was used as internal reference. Right panel,
Log2 FC of ASAP1 upon knockdown. The results were expressed as
mean ± SEM of three independent experiments. c Volcano plot of
DEGs in ASAP1-depleted BT549, Hs578T, and SUM149PT cells. The
red and blue dots indicate down- and upregulated DEGs, respectively,
with p value < 0.05 and absolute Log2 FC >1. d Venn diagram of
down- and upregulated DEGs in BT549, Hs578T, and SUM149PT
TNBC cell lines. Upper panel, downregulated DEGs; lower panel,
upregulated DEGs. Common DEGs denote DEGs popping-up in at
least two cell lines.
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predicted longer relapse-free survival of TNBC patients
with statistical significance (logrank p= 0.00015, HR=
2.76) (Fig. 6d). In contrast, low expression of positive
regulators, which were upregulated by ASAP1 depletion,
implied significantly worse prognosis (logrank p= 0.0092,
HR= 0.47).
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Collectively, our data suggested that amplified ASAP1 is
a key driver in TNBC progression by negatively regulating
cell death pathways. The ASAP1-regulated genes in cyto-
kine, lipid metabolism, and apoptosis signaling pathways
were clinically relevant to TNBC relapse-free survival.
Discussion
TNBC is characterized by its inter-tumoral heterogeneity.
Based on gene expression signatures, TNBC has been fur-
ther classified into more than six molecular subtypes [29],
Yet, no effective molecular targeted therapies are currently
available in the clinic for this type of BC. Although TNBC
demonstrates substantial genetic alterations [30], only two
genes, TP53 and PIK3CA, have been found with mutation
frequency in ~10% of TNBC patient tumors [6], indicating
other driver mutations involved in TNBC progression.
While amplification frequently occurs in cancer genomes,
amplified genes are not always overexpressed [31]. A recent
study has applied integrative analysis combining gene
expression, miRNA and copy number variation genomic
profiles for TNBC patients (n= 137) from TCGA to
reclassify TNBC inter-tumoral heterogeneity [32]. As
overexpression is a requisite for amplified genes to function
as drivers in cancer, we attempted to identify TNBC can-
didate driver genes by integrating DNA copy number
change and mRNA expression omics data across 222
TNBC cases (TCGA dataset n= 118 and Metabric n=
104). Using recurrent event calling algorithm ADMIRE
analysis and transcript expression quantification, we con-
sequently identified 138 genes with frequent focal CNGs
and concurrent high expression in the cohort of TNBC
tumors. Among these genes several are well-known onco-
genes with involvement in BC, e.g., MYC, EGFR, CCNE1,
and FGFR1, consistent to other studies [6, 15, 33]. We also
identified many novel candidates, such as TMEM67,
ANKH, BNIP1, CCT5, ASAP1, and IRF2BP2. KEGG
pathways enrichment displayed the implication of the genes
mainly in cancer-related or oncogenic signaling pathways.
Our integrated genomic analysis reveals frequent CNGs and
amplification as driver mutations in the TNBC genome.
This large group of 138 candidate genes, displaying positive
correlation in recurrent DNA CNGs and high RNA
expression levels in the TNBC genome, may represent
potential drivers during the course of TNBC progression.
CNAs often involve a number of genes within proximity
in the recurrent regions of the same chromosome, resulting
in gene co-amplification. Chromosomal region 8q24
amplification is common in many cancers. Several studies
have reported CNG co-occurrence of numerous genes in
this region, including MYC, ASAP1, PVT1, PTK2, BAI1,
TRIB, and EXT1 [34–38]. Ehlers et al. reported that CNG
in 8q24 strongly correlated with expression of ASAP1 but
not that of MYC in uveal melanoma [34]. By contrast, other
studies demonstrated that co-amplified MYC and PVT1
cooperatively promote tumor progression [37, 38]. In our
TNBC cell lines, 13/20 cell lines represented co-
amplification of MYC and ASAP1; however, our siRNA
studies demonstrated that silencing of ASAP1 alone inhib-
ited TNBC cell proliferation, independently of MYC.
Although both MYC and ASAP1 displayed amplification-
associated prognostic outcome in patients with BC, the
expression of these two genes were poorly correlated in the
same cohort of patients. Our results suggest that co-
amplified MYC and ASAP1 genes are not necessarily
coincidently expressed to promote TNBC tumorigenesis.
Our current siRNA-based proliferation screen validated
several candidate genes promoting TNBC cell proliferative
phenotype, including the known oncogenes MYC and
EGFR and the novel candidates ASAP1, IRF2BP2, CCT5,
and DRD1, indicating the implication of amplification-
dependent drivers in TNBC proliferation. These genes
(except for DRD1) acquired CNG/amplification and high
expression in breast tumors. In particular, amplification of
MYC and ASAP1 is highly frequent in TNBC (35% and
30.3%, respectively) compared with non-TNBC tumors
(25.5% and 22.6%, respectively). The amplification-based
MYC oncogene has been found in various solid tumors,
including kidney and colorectal cancers and BC subtypes,
including TNBC [39, 40], indicating MYC amplification as
a frequent driver mutation in cancer. A recent study has
revealed that MYC alterations are mutually exclusive with
PIK3CA, PTEN, APC, or BRAF alterations [41], suggest-
ing MYC amplification as a distinct driver mutation in the
cancer genome. The novel candidate, ASAP1, has also been
reported to be frequently amplified, accompanied by
enhanced expression, in different types of cancers, includ-
ing pancreatic ductal adenocarcinoma, prostate cancer, and
melanoma [34, 42], exceptionally in primary BC where
overexpression of ASAP1 was described to be independent
of ASAP1 amplification [43]. These early results, though
not reported for BC, underline the impact of ASAP1
Fig. 6 Metascape functional enrichment analysis and TNBC clin-
ical relevance of ASAP1-regulated DEGs. a Top 20 clusters with
their representative enriched term across input of 174 ASAP1-
regulated DEGs. Left panel, heatmap of the 20 enriched terms. One
term per cluster, colored by p values. Log10 (p) is the p value in log
base 10. Right panel, network of the 20 enriched terms, colored by
cluster ID, where nodes that share the same cluster ID are typically
close to each other. b Representative Molecular Complex Detection
(MCODE) network nodes, showing the ASAP1-regulated DEGs
densely connected. c Log2 FC clustering of DEGs involved in cyto-
kine signaling, lipid metabolism, and apoptosis pathways. Blue,
negative regulators; red, positive regulators. d Relapse-free survival
(RFS) KM curves of the DEGs from panel c in patients with TNBC.
Mean expression of positive DEGs (DOWN) or negative DEGs (UP)
was used.
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amplification over the cancer genome. Here, our results
initially interpret that, similar to other cancer types, the
aggressive BC subtype TNBC acquires driver mutations,
such as amplification-dependent overexpression of MYC
and ASAP1, to progress, in spite of genetic heterogeneity.
Of significance for ASAP1, we showed that knockdown of
ASAP1 inhibits cell proliferation in different TNBC cell
lines and high expression of ASAP1 is associated with poor
MRFS of patients with TNBC but not ER+ BC, compelling
the role of ASAP1 in TNBC progression, promoting not
only proliferation but also metastasis.
In this study, we demonstrated for the first time the effect
of ASAP1 on transcriptomic regulation in TNBC cells.
ASAP1 (also named DDEF1 or AMAP1) was identified on
the basis of Arf activity as a phospholipid-dependent Arf
GTPase-activating protein and was found to bind to and be
phosphorylated by Src family proteins and focal adhesion
kinase and to associate with focal adhesions [44, 45]. ASAP1
has been shown to promote cell proliferation and invasion in
different cancer cells, including lung, colorectal, prostate, and
BC cells [18, 42, 46]. High ASAP1 expression level was
found in and was required for invadopodia formation in
invasive MDA-MB-231 TNBC BC cells, and interfering
ASAP1-mediated protein complex inhibited metastasis of
MDA-MB-231-derived xenografts [43]. Overexpression of
ASAP1 has been reported to be associated with poor
metastasis-free survival in prostate, colorectal cancer, and
ovarian cancer and malignant phenotypes of primary BCs
[18, 43, 47]. We showed that depletion of ASAP1 in different
TNBC cells led to reprogramming of gene expression mainly
in cytokine and apoptosis interactive signaling pathways, by
upregulating positive regulators and downregulating negative
regulators of the pathways. For instance, silencing ASAP1
downregulated the components in the identified mitotic cell
cycle G1/S phase transition network node, including the
antiapoptotic APEX1 that is abnormally expressed in
numerous human solid tumors and positively correlated with
cancer progression [48], the proliferation marker MCM6 that
is predictive for poor prognosis in BC [49], and the direct
AKT target RBL2 [50]. In addition, expression of genes
involved in lipid metabolic process was also vulnerable to
ASAP1 depletion, suggesting the novel role of ASAP1 in
metabolism-related tumorigenesis, as lipid metabolism has
been linked to cancer development by causing abnormal
expression of various genes and dysregulating cytokines and
signaling pathways [51]. Most importantly, numerous
ASAP1-regulated genes, particularly those that were down-
regulated when ASAP1 was targeted, displayed significant
relevance to relapse-free survival of TNBC patients, indicat-
ing ASAP1 as an upstream regulator in driving TNBC
progression.
Deconvolution of genetic alterations in cancer genome,
such as focal CNAs, has provided an excellent possibility to
classify new cancer subtypes and identify novel therapeutic
targets for naïve resistant cancers [8, 9, 32]. Our work
elucidated extensive amplification-dependent gene expres-
sion alterations in TNBC, revealing ASAP1 as a potential
TNBC driver functioning upstream of cytokine and apop-
tosis genes in promoting proliferation and survival. ASAP1
emerges as a potential diagnostic marker as well as ther-
apeutic target for cancer, as ASAP1 has been found to be
implicated in multiple oncogenic processes in various can-
cers [18, 42, 47]. Our results suggest that targeting the
upstream regulator ASAP1 and its downstream target genes
may provide actionable therapeutic strategies for over-
coming the intractable TNBC disease, as well as other
resistant cancer types overexpressing ASAP1.
Materials and methods
Cell culture
Human TNBC cell lines BT549, Hs578T, and SUM149PT
were provided by Erasmus Medical Center (Rotterdam, the
Netherlands) and cultured in RPMI-1640 medium supple-
mented with 10% fetal bovine serum, 25 U/ml penicillin
and 25 µg/ml streptomycin in a humidified incubator at
37 °C with 5% CO2. All cell lines were authenticated by
short tandem repeat profiling and subjected to mycoplasma
test using the Mycosensor PCR kit (#302108, Stratagene).
Selection of amplification-dependent candidate
driver genes in TNBC genome by integrated AMDIRE
copy number region analysis and transcript
expression quantification
ADMIRE analysis [20] was performed to detect genomic
regions with recurrent CNGs across 222 triple-negative
tumors (n= 118 from TCGA; n= 104 from Metabric).
Segmented copy number profiles for both TCGA [15] and
the discovery set of Metabric [2] were obtained and used as
input for the ADMIRE analysis. ADMIRE was configured
to control its false discovery rate at 0.01. The recurrently
altered copy number regions identified by ADMIRE were
filtered in order to enrich regions most likely to harbor
driver genes. Importantly, ADMIRE regions may be nested
within larger regions, where the higher nesting levels cor-
respond to more focal and more frequently altered regions.
Our filtering only kept the regions detected at the highest
nesting level. In addition, regions were kept only if they
spanned at least one, but no more than 100 genes. Next, the
genes contained in those regions were identified and
selected as candidate driver genes, if their mRNA expres-
sion profile showed a positive correlation with their copy
number. For this, the RNA-Seq data for TCGA analyzed
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using RSEM transcript quantification and the microarray
expression data for Metabric were applied. The correlation
was tested using Spearman’s correlation, where the Log-
ratio copy number estimates were correlated with the
expression values. Correction for multiple testing was per-
formed by controlling the false discovery rate at 0.1. The
ADMIRE analysis and the subsequent filtering steps were
performed separately for TCGA and Metabric, after which
the resulting gene lists were merged.
siRNA-mediated loss-of-function screen
The primary screen was carried out by use of siGENOME
Human SMARTpool siRNAs (GE Dharmacon, Lafayette,
CO, USA) targeting 138 ADMIRE candidate driver genes.
In the validation screen, SMARTpool siRNA and single
siRNA_1, _2, _3, and _4 that comprise the SMARTpool
mix were used to validate each candidate hit. Cells were
seeded overnight in 96-well plate at an optimized density
for BT549 (8000 cells/96-well), Hs578T (8000 cells/96-
well), and SUM149PT (10,000 cells/96-well), and trans-
fected with 50 nM siRNA by transfection reagent INTER-
FERin (Polyplus-Transfection SA, Illkirch-Graffenstaden,
France) according to the manufacturer’s instructions. We
used a pool of 720 kinase siRNAs at stock concentration of
1 µM in our laboratory as a negative control (siCtrl), this has
no significant effect on expression of any single kinase
genes; siRNA against KIF11 was used as positive control.
The medium was refreshed 24 h post-transfection and
TNBC cells were transfected for 2 days and proliferated for
4 days under indicated condition. SRB colorimetric assay
was used as read-out for cell proliferation [52].
Real-time RT-qPCR assay
Real-time RT-qPCR experiments were performed as pre-
viously described [53]. The primer sequences used were:
forward CAGCCGGCGCTTCCC, reverse ATCAGAAAACG
ACCGGGACC (human ASAP1); forward CTGGTAAAGT
GGATATTGTTGCCAT, reverse TGGAATCATATTGGAAC
ATGTAAACC (human GAPDH). Relative mRNA levels
after correction for GAPDH control mRNA were expressed
using the 2−ΔΔCT method.
DNA copy number alteration and mRNA expression
profiling of candidate genes in breast cancer cell
lines and tumors
DNA copy number data of candidate genes in 20 TNBC cell
lines were obtained from online resources [54]. Log2-based
RNA expression profiles of candidate genes in 52 BC cell
lines was retrieved from our own established RNA-Seq data.
CNAs and mRNA expression of candidate hits in 2173 breast
tumors were obtained from dataset “METABRIC, Nature
2012 & Nat Commun 2016” in cBioPortal (http://www.
cbioportal.org/) [17] and the largest dataset with available
DNA copy number (n= 2173) and mRNA expression (n=
1904) profiles. The 2173 breast tumor samples were filtrated
by the immunohistochemistry status of ER, PR, and HER2,
resulting in 320 triple-negative tumors.
Human whole transcriptome analysis of
ASAP1 silencing effect
TNBC cells were seeded into 96-well plate and transfected
with optimal SMARTpool siRNA targeting ASAP1 (siA-
SAP1), and siRNA control (siCtrl), as described above. The
experiment was performed in biological triplicate. Seventy-
two hours later, cells were washed with PBS and lysed in
80 μl 1× BioSpyder lysis buffer. Lysates were frozen at
−80 °C and shipped to BioSpyder technologies on dry ice
for human whole transcriptome targeted RNA sequencing
TempO-Seq analysis. Expression data for 21,111 transcripts
were generated (BioSpyder Technologies, Inc., Carlsbad,
CA, United States). Normalization and differential expres-
sion analysis were performed using DESeq2 package.
Specifically, each siASAP1 condition was paired with the
corresponding control siCtrl and the counts for each sample
were normalized using the DESeq2 estimateSizeFactors
function. Differential expression of each treatment relative
to its respective control was measured using the Wald test.
With baseMean of counts <10 filtered, genes that were
regulated by siASAP1 with significance (p value < 0.05 and
absolute Log2 FC > 1) were considered significantly DEGs.
Gene functional enrichment analysis of
ASAP1-regulated genes
The DEGs, up- or downregulated by silencing ASAP1,
were uploaded to Metascape [26] (http://metascape.org).
Pathway and process enrichment analyses were carried out
with ontology sources of KEGG pathway, GO Biological
Processes, Reactome Gene Sets, Canonical Pathways, and
CORUM. All genes in the genome were used as the
enrichment background. Terms with p value < 0.01, a
minimum count of 3, and an enrichment factor >1.5 were
collected and grouped into clusters based on their mem-
bership similarities. To further capture the relationship
between the terms of pathways and processes, network of
enriched terms were visualized using Cytoscape, where
each node represents an enriched term and is colored by its
cluster ID. Furthermore, if network contains between 3 and
500 proteins, protein–protein interaction enrichment analy-
sis was carried out with BioGrid, InWeb_IM, and OmniPath
to identify densely connected network components, pre-
sented in Molecular Complex Detection network node.
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Assessment of clinical relevance of candidate genes
to survival prognosis of breast cancer patients
The functionally validated candidate driver genes were
further evaluated using KM analysis for their relation to OS
of 1981 BC patients according to their gene expression [17].
Microarray DNA expression results from BrCa Gene-
Expression Miner were used to classify prognostic asso-
ciation of ASAP1 expression levels with MRFS of 257
TNBC patients (n= 257) and ER+ BC patients (n= 2519)
using “optimal” splitting criterion [16]. The ASAP1-
regulated DEGs involved in cytokine, lipid metabolism,
and apoptosis pathways were assessed for their relation to
relapse-free survival of TNBC patients by KM plotter using
“Auto select best cutoff” [28]. Mean expression of DEGs
was used to assess their prognostic significance.
Statistical analysis
Pearson correlation analysis was performed using GraphPad
Prism 7. Statistical analysis of all experimental data was per-
formed using two-way ANOVA (*p < 0.05, **p < 0.01, ***p
< 0.001). Data were expressed as mean ± SEM of three inde-
pendent experiments. Significance was set at p < 0.05. The
hierarchical clustering in heatmap was performed using
CRAN pheatmap package in RStudio (version 0.99.887).
Data availability
The accession number for the TempO-Seq data generated in
this study is GEO Accession GSE134803.
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